AGS Health ₹4,800 Crore IPO Gets SEBI Nod: Why Is Blackstone Selling ₹3,000 Crore?

AGS Health, a Blackstone-backed healthcare technology company, is preparing for a ₹4,800 crore IPO after receiving SEBI approval in June 2026. The company reported 70.85% revenue growth in FY26, but ₹3,000 crore of the proposed IPO will go to its existing shareholder, Blackstone, rather than the business. With ₹4,238.81 crore in borrowings and negative operating cash flow, investors need to understand whether the company's growth and planned debt repayment make its upcoming IPO worth watching.

Why Is Blackstone Selling ₹3,000 Crore Worth of AGS Health Shares?

AGS Health's proposed IPO has two parts: a ₹1,800 crore fresh issue and a ₹3,000 crore offer for sale (OFS). Blackstone, which controls AGS Health through its investment company BCP Asia II Topco VIII Pte. Ltd., plans to sell existing shares through the OFS.

Blackstone's investment entity held 98.54% of AGS Health before the IPO. The sale will allow it to recover part of its investment, while the fresh issue will help AGS Health repay debt. Such sales are common among private-equity investors, although Blackstone has not publicly confirmed its specific reason for selling this stake.

Source: AGS Health Updated Draft Red Herring Prospectus (UDRHP).

The important distinction is where the money goes. Blackstone will receive the ₹3,000 crore OFS proceeds, while AGS Health will receive the money raised through the fresh issue, after issue expenses.

AGS Health may also raise up to ₹360 crore through a pre-IPO placement, which would reduce the fresh issue size accordingly. For investors, the more important question is how much ownership Blackstone retains after listing and whether the company's financial performance supports its eventual valuation.

What Does AGS Health Do, and How Does It Make Money?

AGS Health helps American hospitals manage medical bills and insurance payments. It does not treat patients or manufacture medicines. Instead, it handles the paperwork and technology-related processes that help hospitals collect money for treatments.

For example, after a patient receives treatment, a hospital submits the bill to the patient's insurance company. If the bill has incorrect medical codes or missing information, the insurer may reject it, delaying payment.

AGS Health helps hospitals prepare these claims, correct rejected bills and follow up on outstanding payments. Hospitals pay AGS Health for managing these services, helping them reduce administrative work and collect payments more efficiently. This business is called Revenue Cycle Management (RCM).

As of March 2026, AGS Health had 149 customers, including 82 hospital and health-system customers. These included 11 of the top 20 US hospitals, according to its IPO disclosures. The growth opportunity comes from American hospitals outsourcing complicated billing work to specialised companies. However, AGS Health must continue winning customers, maintaining service quality and using automation to manage costs as competition increases.

How Strong Are AGS Health's Financials?

AGS Health reported ₹2,041.42 crore in revenue and ₹206.95 crore in net profit for FY26. On paper, revenue increased 70.85% from FY25, but this growth figure needs an important explanation.

Source: AGS Health UDRHP, restated financial information. FY25 numbers are standalone, while FY26 numbers are consolidated.

The company acquired Fort Finance, the holding company of its US business, effective August 2025. As a result, FY26 financial statements include businesses that were not part of the earlier standalone numbers. Therefore, the reported 70.85% revenue increase does not represent like-for-like growth.

To make comparison easier, the IPO filing provides pro forma financials. These show what the combined company's financial performance would have looked like if the acquisition had been included throughout the relevant reporting periods.

Source: AGS Health UDRHP, unaudited pro forma financial information.

These figures show a more comparable revenue growth rate of 21.60%, while the EBITDA margin improved slightly. However, the combined business recorded a larger pro forma loss in FY26.

Why does AGS Health show a ₹206.95 crore reported profit but a ₹141.04 crore pro forma loss?

AGS Health reported 70.85% revenue growth in FY26. However, this increase partly reflects the inclusion of an acquired US business. On a comparable pro forma basis, revenue grew 21.60%, giving investors a clearer picture of the combined company's growth. 

Acquisition-related accounting charges and borrowing costs can significantly affect the final profit. This means investors should not rely only on the reported profit without examining the company's debt, financing expenses and comparable financial results.

How Will AGS Health Use Its IPO Proceeds to Reduce Debt?

AGS Health had consolidated borrowings of ₹4,238.81 crore as of March 31, 2026. It proposes to use ₹1,600 crore from the fresh issue to repay borrowings of two US subsidiaries.

This represents approximately 37.75% of its March 2026 outstanding borrowings. Repaying debt could reduce future interest payments and leave more earnings available for the company. However, substantial borrowings would remain even after the proposed repayment. The exact amount will depend on the company's debt position when the IPO takes place.

Another important concern is cash flow. Despite reporting ₹206.95 crore in net profit, AGS Health recorded negative operating cash flow of ₹126.24 crore in FY26. In simple terms, more cash went out than came in through its operating activities during the year.

Profit and cash flow can differ because some revenue may not yet have been collected, while expenses and other payments require cash. Investors should examine why AGS Health's operating cash flow was negative and whether it improves in subsequent periods.

What Are the Biggest Risks in the AGS Health IPO?

• Dependence on major customers: AGS Health's top 10 customers contributed 59.67% of its pro forma FY26 revenue. Losing a major contract could affect revenue and profitability significantly.
• Dependence on the US healthcare industry: All its revenue comes from US-based healthcare organisations. Changes in insurance rules, healthcare regulations or hospital spending could affect the business.
• High borrowings: The company had ₹4,238.81 crore in debt as of March 2026. Although the IPO could reduce this burden, interest expenses and repayment obligations would remain important.
• Profitability and cash flow: AGS Health reported a pro forma loss of ₹141.04 crore and negative operating cash flow in FY26. It needs to demonstrate that revenue growth can eventually produce consistent profits and cash generation.

These risks are especially important because the company operates in a competitive, technology-driven industry where automation can improve efficiency but also increase pricing pressure.

Is the AGS Health IPO Valuation Attractive for Investors?

AGS Health has not yet announced its IPO price band, making it impossible to determine its final market capitalisation or price-to-earnings (P/E) ratio.

Investors can compare the company with listed healthcare outsourcing businesses such as Inventurus Knowledge Solutions (IKS), but the comparison must account for differences in profitability, debt and services offered.

AGS Health has demonstrated revenue growth and healthy EBITDA margins, but its pro forma losses and substantial borrowings complicate the valuation. A high IPO price would require stronger expectations of future earnings, while a lower valuation could offer more room for business-related uncertainties.

The final price band and updated financial disclosures will therefore be essential before assessing whether the issue is reasonably valued.

Author's Take: What Should Investors Watch Before the AGS Health IPO?

AGS Health's established US hospital relationships and 21.60% pro forma revenue growth indicate a business with expansion potential. The proposed ₹1,600 crore debt repayment could also reduce financial pressure.

However, the headline 70.85% revenue growth does not reflect a like-for-like comparison, while the ₹141.04 crore pro forma loss and negative operating cash flow raise important questions about earnings quality.

Before evaluating the IPO, investors should check three things: how much debt remains after repayment, whether future operating cash flow turns positive, and whether the IPO price is reasonable compared with sustainable earnings.

The biggest question is not simply why Blackstone is selling shares. It is whether AGS Health can convert its growing US healthcare business into consistent profits and cash generation while reducing its debt. That will determine how convincingly the company can support its eventual market valuation.

For more open and upcoming IPOs, visit INDmoney’s IPO tracker.